The first human trial of breast cancer vaccine started in America claims; This will prevent the most dangerous type of triple-negative breast cancer. To prevent breast cancer, the Cleveland Clinic of America has started the trial of the first phase of its vaccine. With the help of this trial, triple-negative breast cancer, the most dangerous type of cancer, can be controlled.
The Cleveland Clinic is working closely with vaccine company Anixa Bioscience after receiving approval for a vaccine trial from the US Food and Drug Administration. Why this trial is special and what it means, let us discuss in detail-
The new vaccine has the potential to prevent breast cancer, says Vincent Tuofi, immunologist and vaccine developer at Cleveland Clinic's Learner Research Institute. Of all the cases of breast cancer, 12 to 15 are triple-negative breast cancer patients. This is the most serious type of breast cancer. Its cases are seen more in African and American women. So it needs to be controlled.
Before the trial, this vaccine was given to patients aged 18 to 24 years suffering from this cancer. Tumors were completely eradicated in these patients. Monitoring is being done to understand the risk of re-tumor in them. In the first phase of the trial, this vaccine will be given to the initial patients suffering from triple-negative breast cancer. To fight cancer, how much immune response is visible in their body, maybe justified with this trial.
Patients involved in the first phase trial will be given three doses of the vaccine. The effect and side effects of the vaccine will be monitored for 2 weeks. This entire trial will be completed by September 2022. The pre-clinical trial of the vaccine was done on rats. During the trial, it was revealed that the vaccine activated the immune system and was successful in preventing breast cancer tumors.
Research published in the journal Nature Medicines says that this vaccine is effective on other tumors. If the first human trial is successful, then this vaccine can make big changes in the medical world.
